Roger Gibson
Family · Topeka, KSNPI 1083681043
Payments from drug & device makers
Across 120 payments — averaging $16.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$557
- Lilly USA, LLC$354
- Novo Nordisk$194
- Amgen$169
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$147
- Exact Sciences$64
- plus $554 from 15 others
What the payments were for
- Food & beverage$2,039100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 40 | $557 |
| Lilly USA, LLC | 19 | $354 |
| Novo Nordisk | 11 | $194 |
| Amgen | 4 | $169 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $147 |
| Exact Sciences | 4 | $64 |
| Antares Pharma, Inc. | 3 | $63 |
| Corium, LLC | 6 | $62 |
| AstraZeneca | 4 | $61 |
| Pfizer | 3 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $45 |
| Boehringer Ingelheim | 3 | $42 |
| Noven Therapeutics, LLC | 2 | $40 |
| Ardelyx, Inc. | 2 | $38 |
| IBSA Pharma Inc. | 2 | $34 |
| Cequr Corporation | 1 | $26 |
| Abbott | 1 | $20 |
| Dynavax Technologies Corporation | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Tolmar, Inc. | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$112
How this compares
$2,039 in reported general payments places this provider in the 85th percentile of 1,579 family providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Irbesartan | 25 | $798 |
| Testosterone Cypionate | 12 | $691 |
| Levothyroxine Sodium | 39 | $594 |
| Atorvastatin Calcium | 69 | $475 |
| Rosuvastatin Calcium | 23 | $440 |
| Tamsulosin Hcl | 27 | $410 |
| Omeprazole | 23 | $383 |
| Losartan Potassium | 16 | $326 |
| Gabapentin | 23 | $305 |
| Potassium Chloride | 17 | $300 |
| Celecoxib | 12 | $271 |
| Lisinopril | 38 | $231 |
| Duloxetine Hcl | 12 | $215 |
| Hydrochlorothiazide | 17 | $189 |
| Tramadol Hcl | 27 | $176 |
Paid to pharmacies, not to this prescriber.
Other family in Topeka
- Tatum TolandTopeka$108K
- Ansley McKennaTopeka$8K
- Jason CrenshawTopeka$7K
- Zohra HussainiKansas City$329K
- Jennifer ChesterOverland Park$327K
- Amanda CaldwellLeawood$203K
- Kayla del RioWichita$147K
- Kelli RiceWichita$114K
- Mary GonzalesWichita$87K
- Erin FeitzOverland Park$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.